Back

Laura Graham, MD

Assistant Professor, Medicine-Medical Oncology

FacultyPhoto
Medical School
  • MD, Rush Medical College of Rush University Medical Center (2015)
Undergraduate School
  • BA, University of Chicago (IL) (2009)
Residency
  • University of Washington Program, Internal Medicine (2018)
Fellowships
  • University of Washington Program, Medical Oncology (2021)
Department Medicine-Medical Oncology

Professional Titles

  • Assistant Professor

Recognitions

  • Nicholas Vogelzang SWOG GU Scholarship, Southwest Oncology Group ( SWOG) (2023)
  • National Comprehensive Care Network (NCCN) Testicular Cancer Guideline Committee Member, NCCN (2023)
  • Paul Calabresi Award for Clinical Oncology Research, NIH (2023)
  • Young Investigator Award, American Society of Clinical Oncology (2021)
  • Chief Fellow, Fred Hutchinson Cancer Research Center (2020)
  • Alpha Omega Alpha Medical Honor Society, Medical Honor Society (2015)

Research Interests

My research focuses on developing more effective treatments for advanced prostate cancer and other genitourinary malignancies through innovative clinical trials and translational science. I am particularly interested in hormone-based therapies, immunotherapy combinations, and T-cell–directed approaches aimed at overcoming treatment resistance and improving durable responses. My work integrates patient care with laboratory investigation, including analyses of blood and tumor samples to better understand how therapies reshape the tumor immune microenvironment and to identify biomarkers that predict which patients are most likely to benefit. I collaborate closely with multidisciplinary academic teams, cooperative groups, and industry partners to accelerate the development of personalized therapies and to translate promising scientific discoveries into meaningful advances for patients with genitourinary cancers.

Publications

  • Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR. Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. JCO Precis Oncol. 2025 Dec;9:e2500590. PubMed PMID: 41348987
  • Panian J, Henderson NC, Herchenhorn D, Barata PC, Bilen MA, Graham L, Heath E, Hwang C, Supernois A, Kilari D, Thapa B, Koshkin VS, Jindal T, Nauseef JT, Sokolova A, Amery T, Zakharia Y, Schweizer MT, Raychaudhuri R, Reichert ZR, Dorff T, Armstrong AJ, Wang J, Alva A, McKay RR. Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. Oncologist. 2025 Nov 11;30(11). PubMed PMID: 41124032
  • Feng BJ, Kohlmann W, Nix DA, Atkinson A, Boucher KM, Carroll C, Stubben CJ, Kolesar J, Singer EA, Riedlinger G, Edge S, Sahu KK, Churchman M, Graham L, Salhia B, Sanchez A, Zakharia Y, Schneider BP, Jain R, Byrne L, Moskaluk CA, Nepple K, Shabsigh A, Chahoud J, Cairns BR, Gupta S. Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape. J Immunother Cancer. 2025 Sep 16;13(9). PubMed PMID: 40962358
  • Orman MV, Graham LS, Cramer SD, Costello JC. Systems biology successes and areas for opportunity in prostate cancer. Endocr Relat Cancer. 2025 Aug 1;32(8). PubMed PMID: 40840524
  • Graham LS, Yu EY. Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer. Clin Cancer Res. 2025 Oct 1;31(19):4001-4003. PubMed PMID: 40742241
  • Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 2025 Jun;10(6):105312. PubMed PMID: 40499462
  • Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025 Apr;23(4). PubMed PMID: 40203876
  • Graham LS, Su LJ, Nicklawsky A, Feng FX, Orlicky D, Petraccione J, Salzmann-Sullivan M, Nordeen SK, Flaig TW. Cell Models of Castration Resistant and High Dose Testosterone-Resistant Prostate Cancer Recapitulate the Heterogeneity of Response Observed in Clinical Practice. Cancers (Basel). 2025 Feb 10;17(4). PubMed PMID: 40002188
  • Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT. Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after (177)Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Eur Urol Oncol. 2025 Feb 6. [Epub ahead of print] PubMed PMID: 39920014
  • Masur J, Ratan A, Wierbilowicz K, Ayanambakkam A, Churchman ML, Graham LS, Grass GD, Gupta S, Kern SQ, King J, Myint Z, Rounbehler RJ, Salhia B, Singer EA, Zakharia Y, Paschal BM, Viscuse PV. Clinical and Genomic Features of Androgen Indifferent Prostate Cancer. Int J Mol Sci. 2025 Jan 15;26(2). PubMed PMID: 39859392
  • Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, Salhia B, Singer EA, Naqash AR, Nepple K, Edge S, Myint Z, Kolesar J, Adra N, Flaig T, Graham LS. Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer. 2025 Feb;23(1):102293. PubMed PMID: 39793235
  • Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):419-426. PubMed PMID: 39019980
  • Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer Prostatic Dis. 2025 Jun;28(2):378-384. PubMed PMID: 38383885
  • Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ, Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S, Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenberg SE, Sanchez A, Thompson RH, Sharma V, Thiel DD, Ball CT, Abreu D, Lam ET, Nahas WC, Master VA, Patel AV, Bernhard JC, Freedman ND, Bigot P, Reis RM, Colli LM, Finelli A, Manley BJ, Terao C, Choueiri TK, Carraro DM, Houlston R, Eckel-Passow JE, Abbosh PH, Ganna A, Brennan P, Gu J, Chanock SJ. Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nat Genet. 2024 May;56(5):809-818. PubMed PMID: 38671320
  • Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta S. Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO Precis Oncol. 2024 Jun;8:e2300697. PubMed PMID: 38976819
  • Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to (177)Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precis Oncol. 2024 Apr;8:e2300634. PubMed PMID: 38662984
  • Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO Precis Oncol. 2024 Apr;8:e2300567. PubMed PMID: 38579192
  • Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2024 Aug;8:e2400014. PubMed PMID: 39178368
  • Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jul 17. [Epub ahead of print] PubMed PMID: 39019980
  • Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta S. Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO Precis Oncol. 2024 Jun;8:e2300697. PubMed PMID: 38976819
  • Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ, Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S, Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenberg SE, Sanchez A, Thompson RH, Sharma V, Thiel DD, Ball CT, Abreu D, Lam ET, Nahas WC, Master VA, Patel AV, Bernhard JC, Freedman ND, Bigot P, Reis RM, Colli LM, Finelli A, Manley BJ, Terao C, Choueiri TK, Carraro DM, Houlston R, Eckel-Passow JE, Abbosh PH, Ganna A, Brennan P, Gu J, Chanock SJ. Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions. Nat Genet. 2024 May;56(5):809-818. PubMed PMID: 38671320
  • Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to (177)Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precis Oncol. 2024 Apr;8:e2300634. PubMed PMID: 38662984
  • Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO Precis Oncol. 2024 Apr;8:e2300567. PubMed PMID: 38579192
  • Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer Prostatic Dis. 2024 Feb 22. [Epub ahead of print] PubMed PMID: 38383885
  • Lakritz S, Nicklawsky A, Alami V, Kohli M, Moskaluk C, Riedlinger G, Salhia B, Singer EA, Naqash AR, Nepple K, Edge S, Myint Z, Kolesar J, Adra N, Flaig T, Graham LS. Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations. Clin Genitourin Cancer. 2024 Dec 12;23(1):102293. [Epub ahead of print] PubMed PMID: 39793235
  • Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2024 Aug;8:e2400014. PubMed PMID: 39178368
  • Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A. Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. Res Sq. 2023 Aug 10. PubMed PMID: 37609284
  • Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK. Management of Prostate Cancer in Older Adults. Am Soc Clin Oncol Educ Book. 2023 May;43:e390396. PubMed PMID: 37207299
  • Gillette CM, Yette GA, Cramer SD, Graham LS. Management of Advanced Prostate Cancer in the Precision Oncology Era. Cancers (Basel). 2023 Apr 29;15(9). PubMed PMID: 37174018
  • Graham LS, Haffner MC, Sayar E, Gawne A, Schweizer MT, Pritchard CC, Coleman I, Nelson PS, Yu EY. Clinical, pathologic, and molecular features of amphicrine prostate cancer. Prostate. 2023 May;83(7):641-648. PubMed PMID: 36779357
  • Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022 Aug;82 Suppl 1:S37-S44. PubMed PMID: 35358351
  • Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. PubMed PMID: 34363009
  • Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022 Aug;82 Suppl 1:S37-S44. PubMed PMID: 35358351
  • Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. PubMed PMID: 34363009
  • Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022 Aug;82 Suppl 1:S37-S44. PubMed PMID: 35358351
  • Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. PubMed PMID: 34363009
  • Graham LS, Sokolova AO, Khaki AR, Wu QV, Davidson NE. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Investigation. 2020 Nov 11:1-4.
  • Graham L, Reder N, Gulati R, Grivas P, Wright J, Yu E, Hou W, Nega K, Yezefski T, Montgomery RB, Mostaghel E, Ellis W, True L, Lin D, Nelson P, Schweizer M. Targeting Backdoor Androgen Synthesis Through AKR1C3 Inhibition: A Presurgical Hormonal Ablative Neoadjuvant Trial in High Risk Localized Prostate Cancer. The Prostate. 2021 Mar: 1-9.
  • Koshkin V, Patel V, Ali A, Bilen M, Ravindranathan D, Park J, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham L, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen S, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Marshall C, Tagawa S, Heath E, Haalbi S, Schweizer M, Armstrong A, Dorff T, Alva A. McKay R. PROMISE: A Real World Clinical-Genomic Database to Address Knowledge Gaps in Prostate Cancer. Prostate Cancer and Prostatic Diseases. 2021 July.
  • Graham L, Prtichard C, Schweizer M. Hypermutation, Mismatch Repair Deficiency and Defining Predictors of Response to Checkpoint Blockade. Clinical Cancer Research. 2021 Sep 27
  • Graham LS, Pritchard CC, Schweizer MT. Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. Clin Cancer Res. 2021 Dec 15;27(24):6662-6665. PubMed PMID: 34580112
  • Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021 May;81(7):418-426. PubMed PMID: 33755225
  • Graham LS, Sokolova AO, Khaki AR, Wu QV, Davidson NE. Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists. Cancer Invest. 2021 Jan;39(1):21-24. PubMed PMID: 33131319
  • Graham L, Montgomery B, Cheng H, Yu E, Nelson P, Pritchard C, Erickson S, Alva A, Schweizer M. Mismatch Repair Deficiency in Metastatic Prostate Cancer (PC): Response to PD-1 Blockade and Standard Therapies. PLoSOne. 2020 May: 15(5). DOI: 10.1371
  • Graham L, Schade G, Schweizer M. Multimodality Treatment of Bilateral Wilms Tumor in a Pregnant Female. Urology. 2019 Sep. DOI: 10.1016
  • Graham L, True L, Schweizer MT. Metastatic Adenocarcinoma of the Epididymis: A Case Report and Brief Literature Review. Clinical Genitourinary Cancer. 2018 Apr;16(2):e335-e338
  • Graham L, Banda K, Torres A, Pisano K, Shelley G, Curley T, Scher H, Lotan T, Hsieh A, Rathkopf D. A Phase II Study of the Dual mTOR inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Investigational New Drugs. 2018 Jun;36(3):458-467
  • Graham L, Schwartz E, Wilson N, Ording J, Daley K, Khandan S, Lake J, Grinder C, Wood-Molo M, Kent PM. Fertility Preservation in Adolescents and Young Adults with Cancer: Patient Behavior and Provider Attitudes. Women’s Reproductive Health. 2017 March; 4 (1): 1-13
  • Graham L, Schweizer MT. Targeting Persistent Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. Med Oncol. 2016 May; 33 (5): 44
  • Yurkovetskiy L, Burrows M, Khan AA, Graham L, Volchkov P, Becker L, Antonopoulos D, Umesaki Y, Chervonsky AV. Gender Bias in Autoimmunity is Influenced by Microbiota. Immunity. 2013 Aug 22;39(2):400–12
  • Graham L, Krass L, Zariffard MR, Spear GT, Mirmonsef P. Effects of Succinic Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages. Biores Open Access. 2013 Oct;2(5):385–91
View All (51 Total) View Less

Professional Memberships

  • American Society of Clinical Oncology (ASCO), Member

Practice Locations

UCHealth Tony Grampsas Urologic Cancer Care Clinic - Anschutz Medical Campus
1665 Aurora Ct
1st Floor
Aurora, CO 80045
720-848-0170

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

Specialties
  • Medical Oncology, Board Certification (2021)
  • Internal Medicine, Board Certification (2018)
  • ABIM Board Certification in Medical Oncology, Board Certification (2021)
  • ABIM Board Certification in Internal Medicine, Board Certification (2018)
Conditions & Treatments
  • Cancers
  • Cancers - Kidney Cancer
  • Cancers - Prostate Cancer
  • Cancers - Testicular Cancer
  • Cancers - Urologic Cancer
  • Cancers - Bladder Cancer
Care Philosophy
My approach to care centers on building a true partnership with each patient and family, grounded in clear and direct communication, compassion, and respect for individual goals and values. As a medical oncologist specializing in genitourinary cancers, I aim to provide evidence-based, personalized treatment while helping patients navigate complex decisions with confidence. I am deeply committed to advancing the field through clinical trials and translational research, with a focus on innovative therapies and understanding why treatments work for some patients and not others. By integrating cutting-edge science with attentive, whole-person care, I strive to offer patients access to the most promising options today while contributing to better treatments for the future. I am seeing patients with prostate cancer, testicular (germ cell) cancer, adrenal cortical cancer, bladder/urothelial cancer, kidney cancer, and rare genitourinary cancers.

General Information

Medical Schools
  • MD, Rush Medical College of Rush University Medical Center (2015)
Undergraduate Schools
  • BA, University of Chicago (IL) (2009)
Residency Programs
  • University of Washington Program, Internal Medicine(2018)
Fellowships
  • University of Washington Program, Medical Oncology (2021)
Department Medicine-Medical Oncology